Dexcom Inc [DXCM] stock is trading at $111.94, down -0.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The DXCM shares have lost -2.33% over the last week, with a monthly amount glided 1.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dexcom Inc [NASDAQ: DXCM] stock has seen the most recent analyst activity on May 30, 2024, when Redburn Atlantic initiated its Neutral rating and assigned the stock a price target of $130. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 12, 2024, and set its price target to $165. Raymond James upgraded its rating to a Strong Buy and increased its price target to $138 on April 17, 2023. UBS initiated its recommendation with a Buy and recommended $142 as its price target on March 29, 2023. Wolfe Research started tracking with a Outperform rating for this stock on January 26, 2023, and assigned it a price target of $121. In a note dated October 18, 2022, Barclays initiated an Equal Weight rating and provided a target price of $103 on this stock.
Dexcom Inc [DXCM] stock has fluctuated between $74.75 and $142.00 over the past year. Currently, Wall Street analysts expect the stock to reach $84.54 within the next 12 months. Dexcom Inc [NASDAQ: DXCM] shares were valued at $111.94 at the most recent close of the market. An investor can expect a potential drop of -24.48% based on the average DXCM price forecast.
Analyzing the DXCM fundamentals
Dexcom Inc [NASDAQ:DXCM] reported sales of 3.80B for the trailing twelve months, which represents a growth of 24.21%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.29 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 110.27 points at the first support level, and at 108.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 113.35, and for the 2nd resistance point, it is at 114.75.
Ratios To Look Out For
For context, Dexcom Inc’s Current Ratio is 2.90. On the other hand, the Quick Ratio is 2.53, and the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 11.71, the price to book ratio is 19.73 and price to earnings (TTM) ratio is 72.27.
Transactions by insiders
Recent insider trading involved Brown Michael Jon, EVP Chief Legal Officer, that happened on Jun 28 ’24 when 659.0 shares were sold. Director, FOLETTA MARK G completed a deal on Jun 18 ’24 to sell 3306.0 shares. Meanwhile, Director FOLETTA MARK G sold 2694.0 shares on Jun 17 ’24.
